91 related articles for article (PubMed ID: 12833654)
1. CDP-870. Celltech/Pfizer.
Rose-John S; Schooltink H
Curr Opin Investig Drugs; 2003 May; 4(5):588-92. PubMed ID: 12833654
[TBL] [Abstract][Full Text] [Related]
2. CDP 571: anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade.
Drugs R D; 2003; 4(3):174-8. PubMed ID: 12757404
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
5. PEG-sTNF-RI. Amgen.
Darlington C
Curr Opin Investig Drugs; 2003 May; 4(5):583-7. PubMed ID: 12833653
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
Baker DE
Rev Gastroenterol Disord; 2008; 8(4):240-53. PubMed ID: 19107098
[TBL] [Abstract][Full Text] [Related]
7. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
Ramiro S; van Tubergen AM; Landewé RB
Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
Ganesan S; Travis SP; Ahmad T; Jazrawi R
Curr Opin Investig Drugs; 2002 Sep; 3(9):1301-6. PubMed ID: 12498004
[TBL] [Abstract][Full Text] [Related]
9. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
Lazebnik LB; Kniazev OV
Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
[No Abstract] [Full Text] [Related]
10. Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent.
Lubrano E; Spadaro A
Acta Biomed; 2011 Apr; 82(1):26-34. PubMed ID: 22069953
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol.
Melmed GY; Targan SR; Yasothan U; Hanicq D; Kirkpatrick P
Nat Rev Drug Discov; 2008 Aug; 7(8):641-2. PubMed ID: 18670430
[TBL] [Abstract][Full Text] [Related]
12. Mucosal healing with anti-TNF antibodies.
Chevaux JB; Vavricka SR; Rogler G; Lakatos PL; Schoepfer A; Peyrin-Biroulet L
Digestion; 2012; 86 Suppl 1():16-22. PubMed ID: 23051722
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
14. IL-1 trap. Regeneron/Novartis.
Gabay C
Curr Opin Investig Drugs; 2003 May; 4(5):593-7. PubMed ID: 12833655
[TBL] [Abstract][Full Text] [Related]
15. [Certolizumab Pegol targets inflammatory processes].
Krankenpfl J; 2005; 43(7-10):231. PubMed ID: 16515300
[No Abstract] [Full Text] [Related]
16. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
19. Cimzia's setback paves way for other TNF inhibitors in Crohn's disease.
Sheridan C
Nat Biotechnol; 2007 May; 25(5):487-8. PubMed ID: 17483820
[No Abstract] [Full Text] [Related]
20. Certolizumab (Cimzia) for Crohn's disease.
Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
[No Abstract] [Full Text] [Related]
[Next] [New Search]
